© 2024 HSP News Service, L.L.C.
In a single-institution study reported in JCO Oncology Practice, Watson et al found that screening for and treating detected dental infections prior to initiation of induction chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) were associated with a significant reduction in ...
Arnon P. Kater, MD, PhD, of the University of Amsterdam, Cancer Center Amsterdam, discusses phase IIIb results from the VENICE I trial, which confirmed that venetoclax monotherapy can achieve deep responses and has a tolerable and manageable safety profile in patients with relapsed or refractory chronic lymphocytic leukemia (Abstract S156).
Jorge E. Cortes, MD, of Georgia Cancer Center, discusses interim results from the OPTIC study, which showed a trend toward dose-dependent efficacy and safety, and may provide a refined understanding of the ponatinib benefit/risk profile and its relation to dose. Mature data from continued follow-up may support an alternate dosing regimen for patients with chronic phase chronic myeloid leukemia (Abstract S172).
John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center, discusses the mature results of a phase II study showing durable remissions and long-term tolerability of acalabrutinib in treatment-naive patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (Abstract S163).
Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings that showed venetoclax and navitoclax with chemotherapy is well tolerated, with promising efficacy in heavily pretreated patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Clinical follow-up, correlative biomarker analysis, and expansion cohort enrollment to assess discontinuous dosing are underway (Abstract S116).
Anthony Moorman, PhD, of Newcastle University, discusses preliminary data showing high-risk patients with acute lymphoblastic leukemia and ABL-class mutations may have improved outcomes when a tyrosine kinase inhibitor is added to chemotherapy (Abstract S117).
Courtney D. DiNardo, MD, of The University of Texas MD Anderson Cancer Center, discusses data from her study of treatment-naive, predominantly older patients with acute myeloid leukemia who are ineligible for intensive therapy. The research shows venetoclax plus azacitidine improved response rates and overall survival compared with azacitidine alone (Abstract LB2601).
Courtney D. DiNardo, MD, of The University of Texas MD Anderson Cancer Center, discusses data from her study of treatment-naive, predominantly older patients with acute myeloid leukemia who are ineligible for intensive therapy. The research shows venetoclax plus azacitidine improved response rates and overall survival compared with azacitidine alone (Abstract LB2601).
Abhishek Maiti, MBBS, of The University of Texas MD Anderson Cancer Center, discusses his analysis showing that 10-day decitabine and venetoclax led to superior outcomes compared with intensive chemotherapy in older patients with acute myeloid leukemia, with benefits most pronounced in people at high risk of treatment-related mortality (Abstract S141).
As reported inThe Lancet by Jeff P. Sharman, MD, of Willamette Valley Cancer Institute/US Oncology, Eugene, Oregon, and colleagues, the phase III ELEVATE-TN trial has shown significantly improved progression-free survival with both acalabrutinib/obinutuzumab and acalabrutinib monotherapy vs...
On June 16, the U.S. Food and Drug Administration (FDA) extended the indication of gemtuzumab ozogamicin (Mylotarg) for newly diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients aged 1 month and older. AAML0531 Efficacy and safety in the pediatric population were...
Advances in the treatment of hematologic malignancies and some of their associated symptoms were presented during EHA25 Virtual, an ongoing online conference from the European Hematology Association (EHA). Advances in the Treatment of High-Risk CLL: CLL2-GIVe Results In the CLL2-GIVe trial, the...
As reported in the Journal of Clinical Oncology by Ghia et al, the phase III ASCEND trial has shown prolonged progression-free survival with acalabrutinib monotherapy vs investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in adult patients with relapsed or refractory...
Farhad Ravandi-Kashani, MD, of The University of Texas MD Anderson Cancer Center, discusses updates from a phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule. It showed early evidence of an acceptable safety profile, drug tolerability, and antileukemic activity, supporting further dose escalation in patients with acute myeloid leukemia (Abstract 7508).
Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses data from a phase II study of pevonedistat plus azacitidine vs azacitidine alone in patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or low-blast acute myeloid leukemia (Abstract 7506).
Formal discussant Yvonne Chen, PhD, Associate Professor of Microbiology, Immunology, and Molecular Genetics at the University of California, Los Angeles, said the issue of toxicity was important, since high levels of toxicity were observed in this small group of five patients. “All five patients...
Chimeric antigen receptor (CAR) T-cell therapy known as TruUCAR GC027 may prove to be useful in the treatment of adult patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and potentially other hematologic malignancies. Preliminary results in a small number of patients...
On April 21, 2020, ibrutinib was granted an expanded indication for use in combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1,2 The recommended dosage of ibrutinib in CLL/SLL is 420 mg, once daily,...
In a phase I/II Children’s Oncology Group study (AAML1421) reported in the Journal of Clinical Oncology, Cooper et al identified the phase II dose of CPX-351, a liposomal preparation of daunorubicin and cytarabine, and found that a regimen consisting of CPX-351 followed by fludarabine, cytarabine,...
Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML) in a phase Ib/II trial. The results of the...
As part of a series of interviews with cancer experts during the COVID-19 pandemic, The ASCO Post spoke with Hagop Kantarjian, MD, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, about the impact of the pandemic on treatment of...
Over the past few weeks, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designations for an antibody-drug conjugate in the treatment of gastric and lung cancers. The Agency has also issued Orphan Drug designations for agents being investigated in chronic myeloid...
The 2019 American Society of Hematology (ASH) Annual Meeting & Exposition featured a cornucopia of sessions. It was impossible to attend all the lectures, symposia, oral presentations, poster presentations, and special events because many were concurrent. Below, we have selected some...
In a study reported in the Journal of Clinical Oncology, Ladas et al found that increased dietary intake of antioxidants was associated with reduced risk for bacterial infection and grade ≥ 3 mucositis during induction therapy in pediatric patients with acute lymphoblastic leukemia (ALL). Study...
For community oncologists treating patients with chronic myeloid leukemia or chronic lymphocytic leukemia during the COVID-19 pandemic, what resources and clinical pearls would you suggest? Recorded April 24, 2020.
At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia? Recorded April 24, 2020.
Are you treating patients with advanced chronic myeloid leukemia (accelerated phase or blast crisis) any differently during the COVID-19 pandemic? Recorded April 24, 2020.
How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia? Recorded April 24, 2020.
In a study reported in the Journal of Clinical Oncology, Getz et al found that use of dexrazoxane was associated with preservation of cardiac function in pediatric patients receiving front-line treatment for acute myeloid leukemia (AML) and resulted in no adverse effects on treatment outcomes. As...
Over the past 2 weeks, the U.S. Food and Drug Administration (FDA) granted Priority Review to a treatment for acute myeloid leukemia (AML); Fast Track designations for agents in pancreatic cancer and pancreatic/nonpancreatic neuroendocrine tumors; approvals for companion diagnostic tests;...
In a study reported in the Journal of Clinical Oncology by Noelle V. Frey, MD, and colleagues, a higher dose of anti-CD19 chimeric antigen receptor (CAR) T cells was associated with a higher rate of complete response in patients with relapsed or refractory chronic lymphocytic leukemia, with...
In a Children’s Oncology Group analysis reported in the Journal of Clinical Oncology, Gupta et al found that discontinuation of pegylated asparaginase (PEG-ASNase) was associated with poorer disease-free survival among pediatric patients with high-risk acute lymphoblastic leukemia (ALL). However,...
As reported in The Lancet by Jeff P. Sharman, MD, and colleagues, the phase III ELEVATE-TN trial showed significantly improved progression-free survival with both acalabrutinib/obinutuzumab and acalabrutinib monotherapy vs chlorambucil/obinutuzumab in patients with treatment-naive chronic...
On April 21, the U.S. Food and Drug Administration (FDA) expanded the indication of ibrutinib (Imbruvica) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This review was conducted...
A new prognostic tool may help to predict time to first treatment for patients with early-stage, asymptomatic chronic lymphocytic leukemia (CLL). Researchers described what they hope will become a point-of-care resource to help improve clinical decision-making in a study published by Rossi et al in ...
Physicians and scientists interested in acute myeloid leukemia (AML) have lost one of the community’s shining lights with the death of Clara D. Bloomfield, MD, FASCO, on March 1, 2020, at age 77 years. Dr. Bloomfield is well known for her more than 50 years of groundbreaking research in blood...
ABSTRACT 355: MURANO study: Four-year analysis confirms sustained benefit (compared to bendamustine and rituximab; n = 195) of time-limited venetoclax/rituximab (n = 194) in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; ClinicalTrials.gov NCT02005471)1...
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for newly diagnosed chronic lymphocytic leukemia (CLL) and...
In a phase I trial reported in The Lancet Oncology, Karol et al found that the combination of the BCL2 inhibitor venetoclax and the chemotherapeutic agent cytarabine with or without idarubicin produced responses in pediatric patients with relapsed or refractory acute myeloid leukemia. As noted by...
In a phase II study reported in the Journal of Clinical Oncology, Robert J. Kreitman, MD, and colleagues found that achievement of minimal residual disease–free complete remission for patients with hairy cell leukemia was enhanced by adding concurrent rituximab to first-line cladribine; a lesser...
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for newly diagnosed and relapsed or refractory acute...
James N. Gerson, MD, Assistant Professor of Medicine at Perelman School of Medicine, University of Pennsylvania, Philadelphia, commented on the implications of the findings from CAPTIVATE. “Upfront therapy for chronic lymphocytic leukemia (CLL) is rapidly evolving. We now have three...
Updated results of the phase II CAPTIVATE trial continue to show high response rates as well as high rates of undetectable minimal residual disease (MRD) with ibrutinib plus venetoclax as front-line treatment of chronic lymphocytic leukemia (CLL) in patients under the age of 70 years. The...
With the availability of a number of effective targeted agents for the treatment of chronic lymphocytic leukemia (CLL), the question arises whether chemotherapy still has a role in treating this malignancy. At the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, CLL...
Javier Pinilla-Ibarz, MD, PhD, of Moffitt Cancer Center, Tampa, Florida, commented on this study: “ELEVATE TN compared front-line treatment with acalabrutinib alone or in combination with obinutuzumab vs obinutuzumab/chlorambucil and showed that a second-generation Bruton’s tyrosine kinase (BTK)...
Ibrutinib was the first Bruton’s tyrosine kinase (BTK) inhibitor to dramatically transform the treatment of patients with chronic lymphocytic leukemia (CLL) and other hematologic malignancies. The second-generation BTK inhibitor acalabrutinib is a more selective BTK inhibitor designed to have an...
Gemtuzumab ozogamicin, once approved in 2000 for the treatment of acute myeloid leukemia (AML), was taken off the market in 2010 due to toxicity concerns. Idarubicin has been used in place of gemtuzumab ozogamicin in some chemotherapy regimens. Gemtuzumab ozogamicin was reintroduced to the market...
The ASH 2019 Annual Meeting & Exposition featured countless important sessions and lectures. It would be impossible to attend all the symposia, oral presentations, poster presentations, and special events. Below, we have selected some presentation highlights to supplement our coverage of the...
Javier Pinilla-Ibarz, MD, PhD, Moffitt Cancer Center, Tampa, Florida, commented on this study: “ELEVATE TN compared front-line treatment with acalabrutinib alone or in combination with obinutuzumab vs obinutuzumab/chlorambucil and showed that a second-generation Bruton’s tyrosine kinase (BTK)...